This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert C. Green, MD; Felicia C. Goldstein, PhD; Alexander P. Auchus, MD; Robyn Presley; W. Scott Clark, PhD; Linda Van Tuyl, RNCS; Joanne Green, PhD; Steven M. Hersch, MD, PhD; Herbert R. Karp, MD

Arch Neurol. 1992;49(11):1135-1136.

Abstract
• Twenty-four carefully assessed patients with probable Alzheimer's disease were enrolled in a double-blind, placebo-controlled treatment study of oxiracetam, a nootropic agent reported to improve memory performance in patients with dementia. A broad battery of neuropsychological tests failed to reveal any improvement in the treated group or in any treated patient when individual test scores were analyzed. These findings indicate that oxiracetam is ineffective in reducing cognitive impairment due to Alzheimer's disease.

Author Affiliations
From the Neurobehavioral Program, Department of Neurology, Emory University School of Medicine and the Wesley Woods Center (Drs R. C. Green, Goldstein, Auchus, J. Green, Hersch, and Karp and Mss Presley and Van Tuyl), and the Division of Biostatistics, Emory University School of Public Health (Dr Clark), Atlanta, Ga.

Footnotes
Accepted for publication June 10, 1992.

Presented in part at the National Academy of Neuropsychology Meeting, Dallas, Tex, October 31, 1991.

Reprint requests to Emory Neurobehavioral Program, Wesley Woods Center, 1821 Clifton Rd NE, Atlanta, GA 30329 (Dr R. C. Green).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?